Targeting Wnt Signaling in Cancer

Guest Editor:

Dr. Robert M. Kypta
Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK; Centre for Cooperative Research in Biosciences, CIC bioGUNE, 48160 Derio, Spain
r.kypta@imperial.ac.uk

Deadline for manuscript submissions:
closed (31 May 2019)

Message from the Guest Editor

Dear Colleagues,

A wide variety of approaches have been used to control Wnt signaling, not only in cancer but also in other diseases where Wnt signaling has gone awry. These approaches include prevention of ligand secretion, inhibition of receptor function, modulation of effector protein stability, and disruption of transcription factor complexes. This Special Issue seeks to highlight some of the achievements that have been made in identifying drugs that target Wnt signaling, in clinical trials involving Wnt inhibitors, and in determining potential new targets and tools that might be used to impact Wnt signaling in cancer in the future.

Dr. Robert M. Kypta
Guest Editor
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI